Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) Gains from Investment Securities: 2018-2024

Historic Gains from Investment Securities for Solid Biosciences (SLDB) over the last 4 years, with Jun 2024 value amounting to -$10,000.

  • Solid Biosciences' Gains from Investment Securities was N/A to -$10,000 in Q2 2024 from the same period last year, while for Jun 2024 it was -$106,000, marking a year-over-year change of. This contributed to the annual value of $407,000 for FY2024, which is 81.99% down from last year.
  • Latest data reveals that Solid Biosciences reported Gains from Investment Securities of -$10,000 as of Q2 2024, which was down 102.40% from $417,000 recorded in Q1 2024.
  • In the past 5 years, Solid Biosciences' Gains from Investment Securities registered a high of $3.1 million during Q4 2020, and its lowest value of -$495,000 during Q4 2023.
  • Moreover, its 3-year median value for Gains from Investment Securities was $174,738 (2022), whereas its average is $152,320.
  • As far as peak fluctuations go, Solid Biosciences' Gains from Investment Securities plummeted by 100.42% in 2021, and later spiked by 298.08% in 2023.
  • Quarterly analysis of 5 years shows Solid Biosciences' Gains from Investment Securities stood at $3.1 million in 2020, then plummeted by 89.77% to $319,000 in 2021, then plummeted by 92.71% to $301,905 in 2022, then surged by 298.08% to -$495,000 in 2023, then plummeted by 40.05% to -$10,000 in 2024.
  • Its Gains from Investment Securities stands at -$10,000 for Q2 2024, versus $417,000 for Q1 2024 and -$495,000 for Q4 2023.